Tirzepatide is a dual agonist for the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors
These studies consistently show: No toxicity, even at high doses Organ-protective and regenerative benefits Absence of tumor formation, cardiovascular damage, or metabolic disruption Despite extensive animal research supporting BPC-157s safety, human safety and pharmacokinetics remain largely unstudied due to its classification as a research chemical. Sikiric, P
628 -opioid receptor agonis Buprenorphine: Transdermal buprenorphine was evaluated in a randomized, double-blind, parallel-group, placebo-controlled trial
We identify ADRB2, BCL3, EGR1, FOS, and MAP3K8 not merely as isolated targets but as components of a disease-associated regulatory network that is upregulated in MASLD
I cant wait to go back! So happy to have microneedling services in the neighborhood